AbstractHIVViral Hepatitis and Liver DiseaseEfavirenz pharmacokinetics in HIV/TB coinfected persons initiating ART while receiving high dose rifapentineView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseIn silico design of a microarray patch as a multipurpose prevention technologyView Abstract
AbstractHIVViral Hepatitis and Liver DiseasePopulation pharmacokinetics of VRC01 in infants and adultsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseThe initial Phase 1 evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next generation HIV maturation inhibitor, as assessed in healthy subjectsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseChanges in drug interaction profiles for first-line HIV therapy over the 20 years of the Liverpool Drug Interaction website.View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseDrugs abuse and chemsex: A new challenge for antiretroviral drug-drug interactionView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEffect of CYP2b6 metabolizer status on levonorgestrel pharmacokinetics when combined with efavirenz-based antiretroviral therapyView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInfectious disease action plan for the global accelerator for paediatric formulations (GAP-f)View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInfant exposure to dolutegravir through placental and breastmilk transfer: A population PK analysis of DolPHIN-1View Abstract
AbstractHIVViral Hepatitis and Liver DiseasePharmacokinetics of atazanavir boosted with cobicistat during pregnancy and postpartumView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseLow isoniazid concentrations in pregnant and postpartum women treated for tuberculosis irrespective of efavirenz-based ART co-treatmentView Abstract
AbstractHIVViral Hepatitis and Liver DiseasePharmacokinetics of tenofovir alafenamide 25 mg with PK boosters during pregnancy and postpartumView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseTenofovir-diphosphate in PBMC following increasing TAF vs. TDF dosing under directly observed therapyView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseAn exploration of adherence measures to detect recent changes in Truvada® dosing patternsView Abstract
AbstractHIVViral Hepatitis and Liver DiseasePhysiologically based pharmacokinetic modelling to determine pharmacokinetic alterations driving ritonavir exposure changes in aging people living with HIVView Abstract
AbstractHIVViral Hepatitis and Liver DiseasePhysiologically-based pharmacokinetic modeling of rilpivirine during pregnancyView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseA semi-mechanistic population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: A study of HIV-infected Zimbabwean adolescentsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseUtilization of physiologically based pharmacokinetic modelling (PBPK) to predict the effect of UGT enzyme inhibition and induction on the systemic exposure of CabotegravirView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseManagement of antiretrovirals in seniors: the importance of assisted treatment for adherence to treatmentView Abstract
AbstractHIVViral Hepatitis and Liver DiseasePharmacokinetics of tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in a client on PrEP after a total gastrectomy with Roux and Y anastomosis (TGRY).View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseProficiency testing supports combined analysis of dolutegravir pharmacokinetic dataView Abstract
AbstractHIVViral Hepatitis and Liver DiseasePlasma and intracellular pharmacokinetics of cobicistat in the clinical settingView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseTemsavir concentration (Cp)-QTc relationship following administration of fostemsavirView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseHepatotoxicity and associated risk factors in HIV-infected patients receiving antiretroviral therapy at a referral hospital in EthiopiaView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseAntiretroviral penetration and drug transporter concentrations in the spleens of three preclinical animal models and humansView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseCharacterization of binding of dolutegravir to plasma proteinsView Abstract
AbstractHIVViral Hepatitis and Liver DiseasePharmacokinetic (PK) and pharmacocokinetic/pharmacodynamic characterization of the two-drug anti-retroviral regimen (2DR) dolutegravir/rilpivirine following switch from current anti-retroviral therapy in the SWORD-1 and SWORD-2 Phase 3 studiesView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseAlteration of hepatic OATP activity does not alter the pharmacodynamic effect of GS-0976, a liver targeted ACC inhibitor, on de novo lipogenesisView Abstract
AbstractHIVViral Hepatitis and Liver DiseasePBPK modelling and simulation of ritonavir-boosted atazanavir (ATV/r) dosing when co-administered with rifampicin (RIF)View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseModel-based simulted 3TC exposure in HIV population by varying renal functionView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseHBV infections among HIV-infected mothers on ART and their exposed infants in a tertiary hospital, Nairobi KenyaView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseTenofovir plasma concentrations in pregnant women: comparison of hepatitis B and HIV-infected patientsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseSofosbuvir and 007 pharmacokinetics among persons with HCV and active drug useView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInfluence of SLCO1B1 polymorphisms on lopinavir plasma concentration in Serbian HIV/AIDS patientsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseComparison of relative bioavailability of pediatric triumeq and pediatric dolutegravir/lamivudine dispersible tablets to conventional film coated tablets in healthy adultsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEffect of tenofovir and bacavir on dolutegravir transport in vitro and in vivoView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseHigh incidence of drug-drug interactions with hepatitis C direct-acting antivirals in patients hospitalized during their treatmentView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseShort-term intravenous proton pump inhibitors and histamine H2 antagonists do not negatively affect sustained virologic response in hepatitis C cirrhotic patients treated with ledipasvir or velpatasvir containing antiviral regimens: a case seriesView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseValproic acid co-administration is not associated with lower non-dolutegravir antiretrovirals’ exposuresView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseThe valproic acid – dolutegravir drug-drug interaction is based on displacement of protein binding and unlikely to be clinically relevantView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseGlecaprevir/pibrentasvir pharmacokinetics in HCV/HIV patients co-administered with antiretroviral drugsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseCobicistat (COBI)-boosted Protease Inhibitors (PIs) plasma and intracellular (IC) pharmacokinetics (PK) in nicotine usersView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseAn assessment of the effects of dolutegravir on gene expression and levonorgestrel clearance in human hepatocytes in vitroView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEvaluating hepatotoxicity of bedaquiline treatment in multi-drug resistant tuberculosis patientsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseRelationship between plasma and intracellular concentrations of bedaquiline and its M2 metabolite in South African patients with drug-resistant TBView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseCo-administration of pretomanid with rifampin or rifabutin among patients with pulmonary TB: interim PK results from “Assessing Pretomanid for Tuberculosis” (APT) trialView Abstract
AbstractHIVViral Hepatitis and Liver DiseasePharmacokinetics and Early Bactericidal Activity of Meropenem (with Amoxicillin/Clavulanate), With and Without Rifampicin, for Drug-Susceptible TBView Abstract
AbstractHIVViral Hepatitis and Liver DiseasePharmacogenetics and pharmacokinetics of first-line anti-tuberculosis drugs in the HIRIF trialView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseIncreased bactericidal activity but dose-limiting tolerability at 50 mg/kg rifampicinView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEthionamide population pharmacokinetic model and Monte Carlo Simulation in patients with multidrug-resistant tuberculosisView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseExposures to first-line drugs in African and Indian children with drug-susceptible tuberculosis using novel fixed-dose-combination tablets at WHO dosing recommendation in the SHINE trialView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseThe OptiRIF study: pharmacokinetics of high-dose rifampicin in childrenView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseCan longitudinal PKPD biomarkers be used to forecast treatment outcome instead of M2 conversion? A population pharmacokinetic-pharmacodynamic analysis in drug sensitive pulmonary tuberculosis.View Abstract
AbstractHIVViral Hepatitis and Liver DiseasePK-PD of isoniazid given at different doses among patients with MDR-TB with INH resistance mediated by inhA mutations: modeling results from ACTG A5312.View Abstract
AbstractHIVViral Hepatitis and Liver DiseasePopulation Pharmacokinetics of Linezolid in TB Patients: Dosing Regimens Simulation and Target Attainment AnalysisView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseLevofloxacin target attainment analysis in MDR-TB patients: time is ripe for proactive TDMView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseAn assay to measure drug tolerance of M. tuberculosis in the caseous center of pulmonary lesionsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseA PBPK modelling approach to simulate the rifampicin-moxifloxacin drug-drug interaction in TB patientsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseStratified dosage regimens from early bactericidal activity studies: an application to pretomanidView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseDrug effect of clofazimine on persistent mycobacteria explain an unexpected increase of bacterial load in patientsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseMechanistic modelling of time-to-positivity and colony-forming unit in tuberculosis patients on high-dose rifampicin to improve understanding of biomarker relationView Abstract
AbstractHIVViral Hepatitis and Liver DiseasePopulation Pharmacokinetics and Model-Informed Precision Dosing of Isoniazid in Tuberculosis PatientsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseOptimal dose individualisation of rifampicin needs to account for between-occasion variabilityView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseLevofloxacin urine kinetics and development of a colorimetric assay for therapeutic drug monitoring among people living with HIV and TBView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseMathematical modeling using in vitro checkerboard assay data: Clofazimine as a potentially synergistic anti-TB drugView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseComparison of a Bayesian forecasting algorithm handling inter-occasion variability and a linear regression approach for dose individualization of rifampicinView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseProtein binding determination of second-line anti-tuberculosis drugs in vitro using an ultrafiltration techniqueView Abstract
